Osteosarcoma (OS) is the most common primary malignant bone tumor in children and adolescents. Unfortunately, chemo-resistance is a huge obstacle in the treatment of OS. However, the underlying molecular mechanisms of OS chemo-resistance still remain unknown. Here we reported that the resistance to camptothecin (cpt) therapy was driven by degradation of DDX5. DDX5 knockdown decreased cell death and DNA damage and recovered cell proliferation in cpt treated 143B cells. Furthermore, we found that DDX5 bound to NONO, a kind of DNA repairing protein, and regulated NONO functions. Our data verified that cpt-induced degradation of DDX5 following by breaking down the protein bound of NONO, which participated in the resistance of cpt. In the summary, according to our results, DDX5 might be a potential therapeutic target for improving clinical outcomes of cpt in OS.

译文

:骨肉瘤(OS)是儿童和青少年中最常见的原发性恶性骨肿瘤。不幸的是,耐化学性是OS治疗的巨大障碍。但是,OS化学抗性的潜在分子机制仍然是未知的。在这里,我们报道了喜树碱(cpt)治疗的耐药性是由DDX5降解引起的。 DDX5组合物降低了cpt处理的143B细胞的细胞死亡和DNA损伤,并恢复了细胞增殖。此外,我们发现DDX5与NONO(一种DNA修复蛋白)结合,并调节NONO功能。我们的数据证实了cpt诱导的DDX5降解是通过破坏NONO的蛋白质结合而引起的,NONO参与了cpt的抗性。总之,根据我们的结果,DDX5可能是改善OS中cpt临床结果的潜在治疗靶标。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录